Trials / Not Yet Recruiting
Not Yet RecruitingNCT06979076
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- MingSight Pharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MS-553, DS1 | Oral, Dose Schedule 1 |
| DRUG | MS-553, DS2 | Oral, Dose Schedule 2 |
Timeline
- Start date
- 2026-07-01
- Primary completion
- 2028-09-01
- Completion
- 2028-12-01
- First posted
- 2025-05-18
- Last updated
- 2025-09-29
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06979076. Inclusion in this directory is not an endorsement.